🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neoplasms, Plasma Cell

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 260 sites📍 Huntsville📍 Phoenix📍 Scottsdale C4 Therapeutics, Inc. · Tests: Cemsidomide, Dexamethasone Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance NCT06483100Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Elrantamab, clonoSEQ Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma NCT05896228Phase 21 site📍 Miami Benjamin T Diamond, MD · Tests: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET NCT05093335EARLY Phase 11 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: [68Ga]-Pentixafor Universal CAR-T Cell Therapy for MM NCT07248176NA1 site📍 Shanghai Bioray Laboratories · Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study NCT06644625n/a1 site📍 Charlotte Wake Forest University Health Sciences · Tests: Blood draw for the laboratory assessment Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy NCT05646576NA1 site📍 Boston Massachusetts General Hospital · Tests: Palliative Care, Usual Care Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) NCT04991103Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: DaraVRD/DaraVCD A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites📍 Bullhead City📍 Los Angeles📍 Pembroke Pines GlaxoSmithKline · Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma NCT07236502NA2 sites📍 Maywood📍 Milwaukee Medical College of Wisconsin · Tests: Immediate intervention, Waitlist A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma NCT07760454Phase 1, Phase 22 sites📍 Suzhou📍 Shanghai UCARsgen Biotech Limited · Tests: CT0596 Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma NCT04234022n/a1 site📍 Wolverhampton The Royal Wolverhampton Hospitals NHS Trust · Tests: Zn-DDC, Lanalidomide with Zn-DDC, Pomalidomide with Zn-DDC Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma NCT06245629n/a1 site📍 Uppsala Uppsala University · Tests: Bortezomib-bendamustine-melphalan A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310Phase 11 site📍 West Hollywood Oncotherapeutics · Tests: Selinexor, Ruxolitinib, Methylprednisolone Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma NCT07200102Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Selinexor A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252Phase 11 site📍 Atlanta OriCell Therapeutics Co., Ltd. · Tests: OriCAR-017 PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) NCT06430736Phase 21 site📍 Bern Insel Gruppe AG, University Hospital Bern · Tests: Tocilizumab before CAR-T cell infusion, Tocilizumab at emerging CRS A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma NCT07477587Phase 184 sites📍 Springdale📍 Jacksonville📍 Margate Shanghai Henlius Biotech · Tests: HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd Prehabilitation Feasibility Among Older Adults Undergoing Transplantation NCT05642884NA1 site📍 Birmingham Noha Mohamed Sharafeldin · Tests: Multi-modal Exercise Regimen, Dietary Guidelines Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment NCT06028087n/a1 site📍 Roma Gruppo Italiano Malattie EMatologiche dell'Adulto Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD NCT05530096n/a1 site📍 Montreal Sir Mortimer B. Davis - Jewish General Hospital · Tests: Standard of care Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. NCT07609576n/a2 sites📍 Madrid📍 Madrid Infanta Leonor University Hospital A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020Phase 3180 sites📍 Daphne📍 Daphne📍 Fairhope Pfizer · Tests: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma NCT07333430Phase 11 site📍 Jerusalem Hadassah Medical Organization · Tests: Naive HBI0101 CAR-T Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044Phase 116 sites📍 Phoenix📍 Orange📍 Jacksonville Jiangsu Simcere Pharmaceutical Co., Ltd. · Tests: SIM0500 Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis NCT06022939Phase 3117 sites📍 Goodyear📍 Tucson📍 Tucson SWOG Cancer Research Network · Tests: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow… A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma NCT07589634Phase 238 sites📍 Goodyear📍 Beverly Hills📍 Irvine Janssen Research & Development, LLC · Tests: Ramantamig, Tocilizumab, Placebo A Clinical Study of SHR-9539 in Patients With Multiple Myeloma NCT06484777Phase 11 site📍 Chengdu Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-9539 for injection A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy